acetylphenylalanyl-prolyl-boroarginine has been researched along with napsagatran in 2 studies
| Studies (acetylphenylalanyl-prolyl-boroarginine) | Trials (acetylphenylalanyl-prolyl-boroarginine) | Recent Studies (post-2010) (acetylphenylalanyl-prolyl-boroarginine) | Studies (napsagatran) | Trials (napsagatran) | Recent Studies (post-2010) (napsagatran) |
|---|---|---|---|---|---|
| 30 | 0 | 0 | 23 | 3 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Verstraete, M | 1 |
2 review(s) available for acetylphenylalanyl-prolyl-boroarginine and napsagatran
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |